How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

887 results for

Rivastigmine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

881. Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months. (Abstract)

Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months. To study the long-term dual inhibitory effects of rivastigmine on acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) in patients with AD.Eleven patients with mild AD received rivastigmine for 12 months. Cholinesterase (ChE) activities in the CSF and plasma were assessed colorimetrically. Immunoblot analysis was used to evaluate AChE isoforms. Neuropsychiatric tests were performed throughout (...) the study.At 12 months, the mean dose of rivastigmine was 8.6 mg/d and specific activities of ChE in the CSF were lower than baseline values (by 36% for AChE and 45% for BuChE), correlating with parallel reductions in the plasma (27% for AChE and 33% for BuChE). The reduction of specific activities in the CSF, but not in the plasma, appeared to be dependent on the dose and duration of treatment. Scores of some of the neuropsychological tests associated with memory and attention were correlated with both

2002 Neurology

882. Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population. Full Text available with Trip Pro

Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population. The management of dementia in Alzheimer's disease has dramatically changed since the development of anti-dementia drugs. However, there is limited information available regarding the bio-medical aspects of the differing drugs; particularly relating to adults with intellectual disability. Indeed (...) the information available for the intellectual disabled population is limited to adults with Down syndrome. This review highlights the important pharmacological and clinical aspects of donepezil, rivastigmine, galantamine and memantine and supports the view that such drugs play an important part in the management of dementia in adults with intellectual disability. Future clinical and research issues are discussed.Copyright 2004 John Wiley & Sons, Ltd.

2004 International Journal of Geriatric Psychiatry

883. Delirium in elderly hospitalised patients: protective effects of chronic rivastigmine usage. (Abstract)

Delirium in elderly hospitalised patients: protective effects of chronic rivastigmine usage. To investigate the efficacy of the chronic usage of the cholinesterase inhibitor rivastigmine in patients with dementia in the prevention of delirium in case of hospitalisation.Retrospective cohort study.Non-geriatric wards of an 1120 bed general teaching hospital in s-Hertogenbosch, The Netherlands.Of a group of 366 hospitalised patients, treated by the geriatric consultation team from January 2002 (...) until June 2003, the patients who used rivastigmine chronically were compared with a randomly selected subgroup of all patients not treated with rivastigmine.The occurrence and duration of a delirium, co-morbidity, use of medication, length of hospitalisation and psychosocial data were collected from the medical charts of the geriatric consultation team.11 patients (3%) were chronic rivastigmine users. A control group of 29 subjects was randomly selected from the non-rivastigmine users

2004 International Journal of Geriatric Psychiatry

884. Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. (Abstract)

Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. Cholinesterase (ChE) inhibitors are primarily used in the treatment of mild to moderate Alzheimer's disease (AD), but may also be effective in more severe disease.To evaluate the dual ChE inhibitor, rivastigmine, in more severe dementia.We retrospectively analysed pooled data from three randomised, placebo-controlled, double-blind, 6-month trials, involving 2126 AD subjects. Subjects were selected according (...) to baseline Mini-Mental State Examination (MMSE) score to identify subjects with more severe cognitive impairment (10-12 MMSE points). One-hundred-and-seventeen subjects were included who had been treated with rivastigmine 6-12 mg/day or placebo. The AD Assessment Scale-Cognitive Subscale (ADAS-Cog), the MMSE, a six-item subscore of the Progressive Deterioration Scale (PDS) and the BEHAVE-AD assessed efficacy. Tolerability was assessed by recording adverse events (AEs) and the relative risk (RR

2004 International Journal of Geriatric Psychiatry

885. Risk of antipsychotic drug use in patients with Alzheimer's disease treated with rivastigmine. (Abstract)

Risk of antipsychotic drug use in patients with Alzheimer's disease treated with rivastigmine. Cholinesterase inhibitors may offer some improvement in the behavioural symptoms of Alzheimer's disease. The dual inhibitory mechanism of action of rivastigmine (inhibition of acetylcholinesterase and butyrylcholinesterase) may improve behavioural symptoms and may delay the need for antipsychotics. This study was conducted to investigate the effect of rivastigmine on the time to first antipsychotic (...) drug use among patients with Alzheimer's disease, compared with patients with Alzheimer's disease not treated with a cholinesterase inhibitor.This study used MarketScan research databases from 1 January 1999 to 31 March 2002. Patients were included if they: (a). were diagnosed with Alzheimer's disease on two occasions or filled a prescription for rivastigmine for the first time during the index period from 1 July 2000 to 31 December 2001; (b). were 65 years of age and older; (c). had continuous

2004 Drugs & Aging

886. Rivastigmine in frontotemporal dementia: an open-label study. (Abstract)

Rivastigmine in frontotemporal dementia: an open-label study. This preliminary open-label study aims to investigate the effects of rivastigmine, an inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), in 20 patients diagnosed with frontotemporal dementia (FTD).Study subjects were men and women 60-75 years of age diagnosed with probable FTD. The rivastigmine group received doses of 3-9 mg/day. The control group included matched patients receiving antipsychotics (...) , benzodiazepines and selegiline (deprenyl). All patients completed a 12-month follow-up period.Rivastigmine treatment was well tolerated. At 12 months, there was a general amelioration of behavioural changes as demonstrated by reductions in Neuropsychiatric Inventory (p<0.001 vs baseline and control), Behavioral Pathology in Alzheimer's Disease Rating Scale (p<0.001 vs baseline and control) and Cornell Scale for Depression in Dementia scores (p<0.05 vs baseline, p<0.001 vs control) in the rivastigmine group

2004 Drugs & Aging

887. Pharmacokinetics and bioavailability of the novel rivastigmine transdermal patch versus rivastigmine oral solution in healthy elderly subjects. (Abstract)

Pharmacokinetics and bioavailability of the novel rivastigmine transdermal patch versus rivastigmine oral solution in healthy elderly subjects. 18199897 2008 05 19 2015 11 19 0091-2700 48 2 2008 Feb Journal of clinical pharmacology J Clin Pharmacol Pharmacokinetics and bioavailability of the novel rivastigmine transdermal patch versus rivastigmine oral solution in healthy elderly subjects. 246-52 10.1177/0091270007312154 Lefèvre Gilbert G Novartis Pharma AG, Exploratory Development, WSJ (...) -210.4.25, CH-4002 Basel, Switzerland. gilbert.lefevre@novartis.com Pommier Françoise F Sedek Greg G Allison Mark M Huang Hsun-Lun Aaron HL Kiese Beate B Ho Yu-Yun YY Appel-Dingemanse Silke S eng Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't England J Clin Pharmacol 0366372 0091-2700 0 3-(1-dimethylaminoethyl)phenol 0 Benzylamines 0 Cholinesterase Inhibitors 0 Phenethylamines 0 Phenols 0 Phenylcarbamates 0 Solutions PKI06M3IW0 Rivastigmine IM Administration, Cutaneous

2008 Journal of clinical pharmacology Controlled trial quality: uncertain

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>